Skip to main content
. Author manuscript; available in PMC: 2022 Oct 10.
Published in final edited form as: Leuk Lymphoma. 2022 Jun 14;63(10):2403–2412. doi: 10.1080/10428194.2022.2084729

Figure 3.

Figure 3.

Impact of peritransplant OH on time to discharge, overall survival and progression free survival. (a) Development of peritransplant did not impact time to discharge. The median time to discharge post-transplant was 14 days (95% CI: 13.6, 14.4) in patients who developed OH versus 14 days (95% CI: 13.4, 14.6) in patients who did not develop OH (p = 0.77). (b) There was no difference in overall survival between patients who developed OH (5-year OS: 57%) and patients who did not develop OH (5-year OS: 58%; p = 0.88). (c) There was no difference in median progressive free survival between patients who developed OH (4.5 years; 95% CI: 3.5, 5.6) and patients who did not develop OH (3.9 years; 95% CI: 2.2, 5.6; p = 0.91).